A detailed history of De Burlo Group Inc transactions in Novo Nordisk A S stock. As of the latest transaction made, De Burlo Group Inc holds 148,730 shares of NVO stock, worth $12.6 Million. This represents 2.19% of its overall portfolio holdings.

Number of Shares
148,730
Previous 172,580 13.82%
Holding current value
$12.6 Million
Previous $24.6 Million 28.11%
% of portfolio
2.19%
Previous 3.36%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$119.07 - $145.42 $2.84 Million - $3.47 Million
-23,850 Reduced 13.82%
148,730 $17.7 Million
Q2 2024

Aug 14, 2024

BUY
$122.71 - $146.91 $6.08 Million - $7.28 Million
49,564 Added 40.29%
172,580 $24.6 Million
Q1 2024

May 13, 2024

BUY
$102.11 - $135.92 $12.6 Million - $16.7 Million
123,016 New
123,016 $15.8 Million
Q3 2022

Nov 14, 2022

SELL
$95.28 - $116.93 $22.5 Million - $27.6 Million
-235,851 Reduced 100.0%
3 $0
Q2 2022

Aug 11, 2022

BUY
$103.24 - $121.81 $24.3 Million - $28.7 Million
235,854 New
235,854 $26.3 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $192B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track De Burlo Group Inc Portfolio

Follow De Burlo Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of De Burlo Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on De Burlo Group Inc with notifications on news.